Ischemic Cerebrovascular Accident
Conditions
Brief summary
The main hypothesis of this work is that an approach combining clinical parameters and biomarker assays could improve the understanding and prediction of the occurrence of silent atrial fibrillation (AF) in the acute phase after stroke. In this prospective work, the investigators will rely on the Dijon Stroke Registry, which collects extensive clinical data for each patient hospitalized for a stroke. As part of this registry, patients are seen 6 months after stroke to assess their clinical status. This clinical follow-up will allow us to judge the evolution of the AF diagnosed during the acute episode at a distance.
Interventions
BIOLOGICALBlood sample
2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
PROCEDURELong term ECG monitor
Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
PROCEDUREMonitoring ECG
Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient who had an ischemic stroke defined according to WHO criteria and hospitalized in the Stroke Unit at the Dijon University Hospital. * Patient 18 years of age and older * Patient who has given oral consent
Exclusion criteria
* Person not affiliated to a national health insurance scheme * Protected adult * Pregnant or breastfeeding woman * Patient refusing to participate in the study * Transfer planned after the stay in the Stroke Unit to a department outside the Dijon University Hospital, not allowing for the long term screening with an external ECG monitor * History of atrial fibrillation or atrial flutter * Patient wearing a pacemaker or defibrillator with an atrial lead
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnosis of atrial fibrillation during continuous monitoring in a Stroke unit within six months of stroke. | 6 months |
Countries
France
Outcome results
None listed